Skip to main content
. 2020 Feb 13;13(2):352–361. doi: 10.1111/cts.12719

Figure 4.

Figure 4

Results of one‐way sensitivity analyses for cost of generic version. Net monetary benefit of brand and generic dabigatran (DAB) with higher‐than‐brand extreme systemic exposure (a) with a willingness‐to‐pay (WTP) threshold of 50,000 (b) with a willingness‐to‐pay threshold of 100,000.